首药控股(688197) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was RMB 707.96 million, representing a decrease of 99.98% compared to the same period last year[7]. - The net profit attributable to shareholders was a loss of RMB 50,662,312.89, with a net profit excluding non-recurring gains and losses of RMB 51,223,077.06[7]. - The company reported a total comprehensive loss of CNY -50,662,312.89 for Q1 2022, reflecting ongoing financial challenges[39]. - The net loss attributable to shareholders for Q1 2022 was CNY -50,662,312.89, compared to a net loss of CNY -34,686,426.61 in Q1 2021[39]. - The net loss for Q1 2022 was 50,070,788.26, compared to a net loss of 33,028,304.44 in Q1 2021[56]. Revenue and Costs - Total operating revenue for Q1 2022 was CNY 707.96 million, a significant decrease from CNY 4,000 million in Q1 2021[36]. - Total operating costs for Q1 2022 reached CNY 51,291,786.21, compared to CNY 38,528,106.66 in Q1 2021[36]. - The company did not recognize any revenue from pharmaceutical cooperation development during the reporting period, leading to a significant decline in operating income[15]. Research and Development - Research and development expenses totaled RMB 46,118,120.32, an increase of 40.40% year-on-year, accounting for 6,514,226.84% of operating revenue[10]. - R&D expenses increased to CNY 46,118,120.32 in Q1 2022, up from CNY 32,847,902.41 in Q1 2021, indicating a focus on innovation[36]. - Research and development expenses increased to 47,507,224.76 in Q1 2022 from 33,396,864.47 in Q1 2021, reflecting a growth of approximately 42.4%[56]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,438,542,169.48, reflecting an increase of 2,372.74% compared to the end of the previous year[10]. - Total liabilities amounted to CNY 108,863,842.04, an increase from CNY 56,674,242.87 year-over-year[36]. - The total liabilities increased to 112,385,793.15 in Q1 2022 from 60,018,128.91 in Q1 2021, representing an increase of approximately 87.2%[56]. - The company reported a total current liability of RMB 95,796,364.42, compared to RMB 53,097,827.45 in the previous year[31]. - The company’s long-term deferred income increased to RMB 13,067,477.62 from RMB 3,576,415.42 year-over-year[31]. Cash Flow - The company reported a net cash flow from operating activities of RMB -31,849,147.69, indicating a negative cash flow situation[7]. - Cash inflow from operating activities totaled ¥15,827,495.14, a significant increase from ¥954,100.16 in the same period last year[44]. - Cash outflow from operating activities amounted to ¥47,676,642.83, compared to ¥38,130,850.92 in Q1 2021, resulting in a net cash flow from operating activities of -¥31,849,147.69[44]. - The cash flow from operating activities showed a net outflow of 31,813,577.98 in Q1 2022, compared to a net outflow of 36,436,390.53 in Q1 2021[58]. Financing Activities - The net cash flow from financing activities increased significantly by RMB 52,302.75 million due to the funds raised from the initial public offering[15]. - The company completed its initial public offering (IPO) of 37.18 million shares at a price of RMB 39.90 per share, raising a total of RMB 1,483.48 million, with a net amount of RMB 1,373.75 million after expenses[23]. - The company raised 1,393,529,683.77 in cash from financing activities in Q1 2022[60]. Current Assets and Inventory - As of March 31, 2022, total current assets amounted to RMB 1,416,177,266.53, a significant increase from RMB 36,458,321.75 in the previous year[28]. - The company’s inventory as of March 31, 2022, was RMB 3,800,507.76, compared to RMB 1,462,705.60 in the previous year[28]. - Total current assets amounted to ¥1,414,567,677.96, a significant increase from ¥35,710,574.95 in the previous year[50]. Shareholder Relations - The company has established significant relationships among its major shareholders, indicating potential strategic alignments[22].